The Chairman's Blog

The Chairman's Blog is an exclusive, online media publication where public and privately held firms alike share insights about their companies and industries.

[The Chairman's Blog @ChairmansBlog]

$DMPI CEO @JeffreyBacha discusses lead product VAL-083 & how it uniquely attacks tumor DNA in his new blog. https://t.co/BNhoaEszh8

[The Chairman's Blog @ChairmansBlog]

.@DelMarPharma CEO penned new blog "Targeting DNA Repair Mechanisms in the Fight Against Cancer." Read here: https://t.co/BNhoaEszh8 $DMPI

[The Chairman's Blog @ChairmansBlog]

Read @Pluristem President & COO Yaky Yanay's new post "Biotech Nation" discussing Israel's growing #biotech industry https://t.co/opL4gyPj92

[The Chairman's Blog @ChairmansBlog]

$DMPI CEO @JeffreyBacha penned new blog discussing the Company's decision to execute a reverse stock split. https://t.co/Wct9CufFek

[The Chairman's Blog @ChairmansBlog]

Read DelMar CEO's new blog "Reverse Stock Splits & Uplisting" here: https://t.co/Wct9CufFek

[The Chairman's Blog @ChairmansBlog]

.@JeffreyBacha highlights @60minutes update on @DukeU's #braincancer treatment & potential of chemo-immunoncology https://t.co/tZLZUvqtmu

[The Chairman's Blog @ChairmansBlog]

$DMPI CEO discusses the Company's chemotherapy VAL-083 for #GBM & its potential to be used w/ immunotherapies here: https://t.co/tZLZUv8SuW

[The Chairman's Blog @ChairmansBlog]

DelMar CEO penned new blog, "60 Minutes, Polio Virus for GBM, and the Promise of Chemo-Immunooncology." Read here: https://t.co/tZLZUvqtmu

[The Chairman's Blog @ChairmansBlog]

$DMPI CEO highlights importance of data from #AACR16 supporting VAL-083 & potential to target underserved #cancers https://t.co/VF09DtKEQb

[The Chairman's Blog @ChairmansBlog]

$DMPI CEO @JeffreyBacha discusses new data presented at #AACR16 supporting the distinct mechanism of VAL-083. https://t.co/VF09DtKEQb

[The Chairman's Blog @ChairmansBlog]

.@DelMarPharma CEO penned new blog "Mechanism Matters." Read here: https://t.co/VF09DtKEQb $DMPI

[The Chairman's Blog @ChairmansBlog]

.@SysorexGlobal CTO discusses the ROI of real time #IoT #analytics in his new post "Where’s the Money in IoT?" https://t.co/yTr7RhrOno $SYRX

[The Chairman's Blog @ChairmansBlog]

Read the latest blog by @SysorexGlobal Chief Technology Officer: "What’s Better than First? Last." https://t.co/pgRpKfYYkj $SYRX

[The Chairman's Blog @ChairmansBlog]

$DMPI CEO highlights how DelMar has potential to independently commercialize VAL-083 in his new blog: https://t.co/eloWdXGc5c

[The Chairman's Blog @ChairmansBlog]

$DMPI CEO discusses 3 key elements he feels a company needs in order to independently bring a treatment to market. https://t.co/eloWdXGc5c

[The Chairman's Blog @ChairmansBlog]

DelMar CEO pens new blog "Unlocking the Value of Independent Commercialization." Read here: https://t.co/eloWdXGc5c

[The Chairman's Blog @ChairmansBlog]

DelMar CEO pens new blog, "GBM After Rintegra®." Read here: https://t.co/AjNy17Hpmi $DMPI $CLDX

[The Chairman's Blog @ChairmansBlog]

A new blog from $DMPI CEO "Modernizing Medicines: DelMar’s Strategic Edge for VAL-083 in Oncology": https://t.co/bNFhXbwLFQ

[The Chairman's Blog @ChairmansBlog]

.@DelMarPharma CEO discusses how modern understanding of #tumor biology gives VAL-083 a strategic edge in #oncology. https://t.co/bNFhXbwLFQ

[The Chairman's Blog @ChairmansBlog]

.@DelMarPharma CEO @JeffreyBacha penned a new blog discussing lead drug candidate VAL-083: https://t.co/bNFhXbwLFQ $DMPI